

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 JAN 27 Source of Registration (SR) information in REGISTRY updated  
and searchable  
NEWS 4 JAN 27 A new search aid, the Company Name Thesaurus, available in  
CA/CAPLUS  
NEWS 5 FEB 05 German (DE) application and patent publication number format  
changes  
NEWS 6 MAR 03 MEDLINE and L MEDLINE reloaded  
NEWS 7 MAR 03 MEDLINE file segment of TOXCENTER reloaded  
NEWS 8 MAR 03 FRANCEPAT now available on STN  
NEWS 9 MAR 29 Pharmaceutical Substances (PS) now available on STN  
NEWS 10 MAR 29 WPIFV now available on STN  
NEWS 11 MAR 29 No connect hour charges in WPIFV until May 1, 2004  
NEWS 12 MAR 29 New monthly current-awareness alert (SDI) frequency in RAPRA  
  
NEWS EXPRESS MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 13 APRIL 2004  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 07:19:41 ON 19 APR 2004

=> FIL STNGUIDE

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'STNGUIDE' ENTERED AT 07:19:47 ON 19 APR 2004

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE

AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Apr 16, 2004 (20040416/UP).

=> FIL HOME

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.06

0.27

FILE 'HOME' ENTERED AT 07:19:51 ON 19 APR 2004

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.48

FILE 'REGISTRY' ENTERED AT 07:19:56 ON 19 APR 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 16 APR 2004 HIGHEST RN 676095-08-2

DICTIONARY FILE UPDATES: 16 APR 2004 HIGHEST RN 676095-08-2

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.


Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more  
information enter HELP PROP at an arrow prompt in the file or refer  
to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Examination Auxillary files\10076318\10076318 elected specie.str



chain nodes :

2 3 4 5 11 12 13 14 15 18 19 20 21 22 23 24 25 26 27 28 29 30  
35 36 37

```

ring nodes :
1  6  7  8  9  10 16 17 31 32 33 34
chain bonds :
1-2  2-3  3-4  3-25 3-26 4-5  4-27 5-28 7-11 11-12 12-13 13-14 13-18 14-15
14-29 15-16 15-30 18-19 19-20 20-21 21-22 22-23 23-24 32-35 35-36 35-37

ring bonds :
1-6  1-10 6-7  7-8  8-9  9-10 16-17 16-34 17-31 31-32 32-33 33-34
exact/norm bonds :
1-2  2-3  12-13 13-14 13-18 14-15 14-29 15-16
exact bonds :
3-4  3-25 3-26 5-28 7-11 11-12 15-30 18-19 19-20 20-21 21-22 22-23 23-24
32-35 35-36 35-37
normalized bonds :
1-6  1-10 4-5  4-27 6-7  7-8  8-9  9-10 16-17 16-34 17-31 31-32 32-33 33-34

Match level :
1:Atom 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:Atom 17:Atom 18:CLASS
19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS
27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:Atom 32:Atom 33:Atom 34:Atom
35:CLASS 36:CLASS 37:CLASS


```

L1        STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1                STR



Structure attributes must be viewed using STN Express query preparation.

=> search l1 sss sam  
SAMPLE SEARCH INITIATED 07:20:37 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 5 TO ITERATE

100.0% PROCESSED 5 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 5 TO 234  
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> search l1 sss full  
FULL SEARCH INITIATED 07:20:48 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 53 TO ITERATE


100.0% PROCESSED 53 ITERATIONS 3 ANSWERS  
SEARCH TIME: 00.00.01

L3 3 SEA SSS FUL L1

=> d scan


L3 3 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN  
IN Butanoic acid, 2-[3-[2-[heptyl[[[4-(1-methylethyl)phenyl]amino]carbonyl]amino]ethyl]phenoxy]-2-methyl-, (2R)- (9CI)  
MF C30 H44 N2 O4

Absolute stereochemistry.




HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L3 3 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN  
IN Propanoic acid, 2-[3-[2-[heptyl[[[4-(1-methylethyl)phenyl]amino]carbonyl]amino]ethyl]phenoxy]-2-methyl- (9CI)  
MF C29 H42 N2 O4



L3 3 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN  
 IN Butanoic acid, 2-[3-[2-[heptyl[[[4-(1-methylethyl)phenyl]amino]carbonyl]amino]ethyl]phenoxy]-2-methyl- (9CI)  
 MF C30 H44 N2 O4



ALL ANSWERS HAVE BEEN SCANNED

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

155.84

156.32

FILE 'CAPLUS' ENTERED AT 07:21:12 ON 19 APR 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Apr 2004 VOL 140 ISS 17

FILE LAST UPDATED: 18 Apr 2004 (20040418/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> l3

L4 1 L3

=> d l4 ti fbib abs

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN

TI Phenoxyalkanoic acids as peroxisome proliferator activator receptor

(PPAR $\alpha$ ) agonists  
 AN 2002:637514 CAPLUS  
 DN 137:185319  
 TI Phenoxyalkanoic acids as peroxisome proliferator activator receptor  
 (PPAR $\alpha$ ) agonists  
 IN Hayward, Cheryl Myers; Perry, David Austen  
 PA Pfizer Products Inc., USA  
 SO PCT Int. Appl., 147 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002064130	A1	20020822	WO 2002-IB43	20020109
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
				US 2001-269057PP	20010215
EP	1372632	A1	20040102	EP 2002-740088	20020109
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
				US 2001-269057PP	20010215
				WO 2002-IB43	W 20020109
BR	2002007227	A	20040210	BR 2002-7227	20020109
				US 2001-269057PP	20010215
				WO 2002-IB43	W 20020109
US	2002169192	A1	20021114	US 2002-76318	20020214
				US 2001-269057PP	20010215

OS MARPAT 137:185319  
 AB 3-AWEN(CH2R3)12CR5R6C6H4BCR1R2Z [A = H, (un)substituted NH2, alkoxy, aryl, cycloalkyl, heterocyclic; W = bond, (un)substituted NH, azaalkylene, alkylene, cycloalkylene; E = CO, SO2; B = O, S, S(O), SO2, CH2, NH; Z = CO2H, CHO, CH2OH, alkoxycarbonyl, CN, CONHOH, tetrazolyl, tetrazolylaminocarbonyl, 4,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl, 3-oxoisoxazolidin-4-ylaminocarbonyl, CONHSO2R4; R1 = H, alkyl, cycloalkyl; R2 = H, cycloalkyl, (un)substituted alkyl; R3 = (un)substituted alkyl, alkenyl, alkynyl; R4 = (un)substituted alkyl, NH2; R5, R6 = H, alkyl, cycloalkyl, cycloalkylalkyl; CR5R6 = carbocyclic] were prepared for use as PPAR $\alpha$  activators (no data). These compds. elevate certain plasma lipid levels, including HDL-cholesterol and lower certain plasma lipid levels, such as LDL-cholesterol and triglycerides and are used to treat diseases which are exacerbated by low levels of HDL-cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans. Thus, 3-MeOC6H4CH2CH2NH2 was demethylated, converted to the amide with heptanoic acid, and treated with Cl3CCMeEtOH to give 3-Me(CH2)5CONHCH2CH2C6H4OCMeEtCO2H which was converted to the benzyl ester and reduced to 3-Me(CH2)6NHCH2CH2C6H4OCMeEtCO2CH2Ph. This ester was treated with 2,4-F2C6H3NCO and debenzylated to give 3-Me(CH2)6N(CONHC6H3F2-2,4)CH2CH2C6H4OCMeEtCO2H.

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff hold

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST	ENTRY 3.42	SESSION 159.74
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY -0.69	SESSION -0.69

SESSION WILL BE HELD FOR 60 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 07:22:34 ON 19 APR 2004

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1	Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	"Ask CAS" for self-help around the clock
NEWS 3 JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS 4 JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAPLUS
NEWS 5 FEB 05	German (DE) application and patent publication number format changes
NEWS 6 MAR 03	MEDLINE and LMEADLINE reloaded
NEWS 7 MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS 8 MAR 03	FRANCEPAT now available on STN
NEWS 9 MAR 29	Pharmaceutical Substances (PS) now available on STN
NEWS 10 MAR 29	WPIFV now available on STN
NEWS 11 MAR 29	No connect hour charges in WPIFV until May 1, 2004
NEWS 12 MAR 29	New monthly current-awareness alert (SDI) frequency in RAPRA
NEWS EXPRESS	MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 APRIL 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 10:00:49 ON 19 APR 2004

=> logoff hold  
COST IN U.S. DOLLARS  
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

SESSION WILL BE HELD FOR 60 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 10:00:57 ON 19 APR 2004

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1	Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	"Ask CAS" for self-help around the clock
NEWS 3 JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS 4 JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CaPlus
NEWS 5 FEB 05	German (DE) application and patent publication number format changes
NEWS 6 MAR 03	MEDLINE and LMedline reloaded
NEWS 7 MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS 8 MAR 03	FRANCEPAT now available on STN
NEWS 9 MAR 29	Pharmaceutical Substances (PS) now available on STN
NEWS 10 MAR 29	WPIFV now available on STN
NEWS 11 MAR 29	No connect hour charges in WPIFV until May 1, 2004
NEWS 12 MAR 29	New monthly current-awareness alert (SDI) frequency in RAPRA
NEWS EXPRESS	MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 APRIL 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 11:41:50 ON 19 APR 2004

=> file reg  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
------------	-------



FULL ESTIMATED COST

ENTRY

0.21

SESSION

0.21

FILE 'REGISTRY' ENTERED AT 11:42:02 ON 19 APR 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 18 APR 2004 HIGHEST RN 676118-37-9

DICTIONARY FILE UPDATES: 18 APR 2004 HIGHEST RN 676118-37-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004



Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more  
information enter HELP PROP at an arrow prompt in the file or refer  
to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Examination Auxillary files\10076318\10076318 try 2.str



chain nodes :

2 3 4 5 11 12 13 14 15 16 17 18 19

ring nodes :

1 6 7 8 9 10

chain bonds :

1-2 2-3 3-4 4-5 4-17 5-18 7-11 11-12 12-13 13-14 13-15 14-19 15-16

ring bonds :

1-6 1-10 6-7 7-8 8-9 9-10

exact/norm bonds :

1-2 2-3 12-13 13-14 13-15 14-19

exact bonds :

3-4 5-18 7-11 11-12 15-16

normalized bonds :

1-6 1-10 4-5 4-17 6-7 7-8 8-9 9-10

Match level :


1:Atom 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS  
19:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> search l1 sss sam

SAMPLE SEARCH INITIATED 11:44:02 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 9 TO ITERATE

100.0% PROCESSED 9 ITERATIONS

3 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 9 TO 360

PROJECTED ANSWERS: 3 TO 163

L2 3 SEA SSS SAM L1


=> d scan

L2 3 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN

IN Butanoic acid, 2-[3-[2-[[[(2,4-difluorophenyl)amino]carbonyl]heptylamino]ethyl]phenoxy]-2-methyl-, (2S)- (9CI)


MF C27 H36 F2 N2 O4

Absolute stereochemistry.




HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L2 3 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN  
 IN Butanoic acid, 2-[3-[2-[[[(3,5-dimethoxyphenyl)amino]carbonyl]heptylamino]ethyl]phenoxy]-2-methyl- (9CI)  
 MF C29 H42 N2 O6



L2 3 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN  
 IN Butanoic acid, 2-[3-[2-[[[(4-fluorophenyl)amino]carbonyl]heptylamino]ethyl]phenoxy]-2-methyl- (9CI)  
 MF C27 H37 F N2 O4



ALL ANSWERS HAVE BEEN SCANNED

=> search l1 sss full  
 FULL SEARCH INITIATED 11:44:57 FILE 'REGISTRY'  
 FULL SCREEN SEARCH COMPLETED - 292 TO ITERATE

100.0% PROCESSED 292 ITERATIONS  
 SEARCH TIME: 00.00.01


75 ANSWERS

L3 75 SEA SSS FUL L1

=> d scan


L3 75 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN

IN Butanoic acid, 2-[3-[2-[[[2-(2,4-difluorophenyl)ethyl]amino]carbonyl]pent  
ylamino]ethyl]phenoxy]-2-methyl- (9CI)  
MF C27 H36 F2 N2 O4




HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):10

L3 75 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN  
IN Butanoic acid, 2-[3-[2-[(2,4-dimethoxybenzoyl)heptylamino]ethyl]phenoxy]-2-  
methyl- (9CI)  
MF C29 H41 N O6




L3 75 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN  
IN Butanoic acid, 2-[3-[2-[heptyl[(4-hydroxyphenyl)acetyl]amino]ethyl]phenoxy  
]-2-methyl- (9CI)  
MF C28 H39 N O5




L3 75 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN  
IN Butanoic acid, 2-[3-[2-[[[(4-ethylphenyl)amino]carbonyl]heptylamino]ethyl]  
phenoxy]-2-methyl-, (2R)- (9CI)  
MF C29 H42 N2 O4

Absolute stereochemistry.




L3 75 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN  
 IN Butanoic acid, 2-[3-[2-[[[(3,4-difluorophenyl)amino]carbonyl]heptylamino]ethyl]phenoxy]-2-methyl- (9CI)  
 MF C27 H36 F2 N2 O4




L3 75 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN  
 IN Butanoic acid, 2-[3-[2-[[[(2,4-difluorophenyl)amino]carbonyl]heptylamino]ethyl]phenoxy]-2-methyl-, (2R)- (9CI)  
 MF C27 H36 F2 N2 O4


Absolute stereochemistry.



L3 75 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN  
 IN Butanoic acid, 2-[3-[2-[heptyl(1H-indol-3-ylacetyl)amino]ethyl]phenoxy]-2-methyl- (9CI)  
 MF C30 H40 N2 O4




L3 75 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN  
 IN Butanoic acid, 2-[3-[2-[[2-(2,4-difluorophenyl)ethyl] (1-oxo-3-phenylpropyl)amino]ethyl]phenoxy]-2-methyl- (9CI)  
 MF C30 H33 F2 N O4




L3 75 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN  
 IN Butanoic acid, 2-[3-[2-[[2-(2,4-difluorophenyl)ethyl] [(pentylamino)carbonyl]amino]ethyl]phenoxy]-2-methyl-, (2S)- (9CI)  
 MF C27 H36 F2 N2 O4

Absolute stereochemistry.



L3 75 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN  
 IN Butanoic acid, 2-[3-[2-[heptyl[[[4-(trifluoromethoxy)phenyl]amino]carbonyl]amino]ethyl]phenoxy]-2-methyl- (9CI)  
 MF C28 H37 F3 N2 O5



L3 75 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN  
 IN Acetic acid, [3-[2-[[[(2,4-dimethoxyphenyl)amino]carbonyl]heptylamino]ethyl

MF



HON


L3

L3


L3

L3


lamino]ethyl]phenoxy]-2-methyl- (9CI)  
 MF C28 H38 F2 N2 O4



L3 75 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN  
 IN Butanoic acid, 2-[3-[2-[[4-(2,4-difluorophenyl)acetyl]heptylamino]ethyl]phenoxy]-  
 2-methyl- (9CI)  
 MF C28 H38 F2 N2 O4




L3 75 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN  
 IN Butanoic acid, 2-[3-[2-[[2,4-difluorophenyl]acetyl]heptylamino]ethyl]phen  
 oxy]-2-methyl- (9CI)  
 MF C28 H37 F2 N2 O4




L3 75 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN  
 IN Butanoic acid, 2-[3-[2-[heptyl[(4-hydroxyphenyl)acetyl]amino]ethyl]phenoxy]  
 ]-2-methyl-, (2S)- (9CI)  
 MF C28 H39 N O5

Absolute stereochemistry.







L3 75 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN  
 IN Butanoic acid, 2-[3-[2-[[[4-(4-fluorophenyl)amino]carbonyl]heptylamino]ethyl]phenoxy]-2-methyl- (9CI)  
 MF C27 H37 F N2 O4



L3 75 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN  
 IN Propanoic acid, 2-[3-[2-[[[2,4-dimethoxyphenyl]amino]carbonyl]heptylamino]ethyl]phenoxy]-2-methyl- (9CI)  
 MF C28 H40 N2 O6



L3 75 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN  
 IN Butanoic acid, 2-[3-[2-[heptyl[(3-methoxyphenyl)acetyl]amino]ethyl]phenoxy]-2-methyl- (9CI)  
 MF C29 H41 N O5



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):\0  
 '\0' IS NOT VALID HERE

To display more answers, enter the number of answers you would like to see. To end the display, enter "NONE", "N", "0", or "END".  
HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

157.94

158.15

FILE 'CAPLUS' ENTERED AT 11:45:58 ON 19 APR 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Apr 2004 VOL 140 ISS 17

FILE LAST UPDATED: 18 Apr 2004 (20040418/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> 13

L4 1 L3

=> d l4 ti fbib abs

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN

TI Phenoxyalkanoic acids as peroxisome proliferator activator receptor (PPAR $\alpha$ ) agonists

AN 2002:637514 CAPLUS

DN 137:185319

TI Phenoxyalkanoic acids as peroxisome proliferator activator receptor (PPAR $\alpha$ ) agonists

IN Hayward, Cheryl Myers; Perry, David Austen

PA Pfizer Products Inc., USA

SO PCT Int. Appl., 147 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2002064130	A1	20020822	WO 2002-IB43	20020109

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG



Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'CAPLUS' AT 11:52:56 ON 19 APR 2004  
FILE 'CAPLUS' ENTERED AT 11:52:56 ON 19 APR 2004  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	7.05	165.20

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-0.69	-0.69

=> file reg

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	7.05	165.20

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-0.69	-0.69

FILE 'REGISTRY' ENTERED AT 11:53:08 ON 19 APR 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 18 APR 2004 HIGHEST RN 676118-37-9  
DICTIONARY FILE UPDATES: 18 APR 2004 HIGHEST RN 676118-37-9

TSKA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004



Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more  
information enter HELP PROP at an arrow prompt in the file or refer  
to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Examination Auxillary files\10076318\10076318 try 2 obv.str



```

chain nodes :
2 3 4 5 11 12 13 14 15 16 17 18 19
ring nodes :
1 6 7 8 9 10
chain bonds :
1-2 2-3 3-4 4-5 4-17 5-18 11-12 12-13 13-14 13-15 14-19 15-16
ring bonds :
1-6 1-10 6-7 7-8 8-9 9-10
exact/norm bonds :
1-2 2-3 12-13 13-14 13-15 14-19
exact bonds :
3-4 5-18 11-12 15-16
normalized bonds :
1-6 1-10 4-5 4-17 6-7 7-8 8-9 9-10

```

```

Match level :
1:Atom 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS


```

L6 STRUCTURE UPLOADED

=> d 16

L6 HAS NO ANSWERS

L6 STR



Structure attributes must be viewed using STN Express query preparation.

=> search l6 sss sam

SAMPLE SEARCH INITIATED 11:54:02 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 171 TO ITERATE

100.0% PROCESSED 171 ITERATIONS

7 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 2636 TO 4204

PROJECTED ANSWERS: 7 TO 298


L7 7 SEA SSS SAM L6

=> d scan

L7 7 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN

IN Propanoic acid, 2-[4-[2-[heptyl[(2,4,6-trimethylphenyl)amino]carbonyl]amino]ethyl]phenoxy]-2-methyl- (9CI)

MF C29 H42 N2 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> search l6 sss full

FULL SEARCH INITIATED 11:54:45 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 3488 TO ITERATE

100.0% PROCESSED 3488 ITERATIONS

111 ANSWERS

SEARCH TIME: 00.00.01

L8 111 SEA SSS FUL L6

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
156.26	321.46

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-0.69

CA SUBSCRIBER PRICE

FILE 'CAPLUS' ENTERED AT 11:54:56 ON 19 APR 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Apr 2004 VOL 140 ISS 17

FILE LAST UPDATED: 18 Apr 2004 (20040418/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> l8

L9 31 L8

=> d l9 21-31 ti

L9 ANSWER 21 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN

TI Pharmaceutical compositions containing ACAT and MMP inhibitors for the treatment of atherosclerotic lesions

L9 ANSWER 22 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN

TI A Ureido-Thioisobutyric Acid (GW9578) Is a Subtype-Selective PPAR $\alpha$  Agonist with Potent Lipid-Lowering Activity

L9 ANSWER 23 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN

TI Direct tritium labeling of multifunctional compounds using organoiridium catalysis. 2

L9 ANSWER 24 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN

TI Identification of peroxisome proliferator-activated receptor ligands from a biased chemical library

L9 ANSWER 25 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN

TI Generation of secondary alkyl amines on solid support by borane reduction. Applications to the parallel synthesis of PPAR ligands. [Erratum to document cited in CA127:220440]

L9 ANSWER 26 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN

TI Prevention or treatment of type 2 diabetes or cardiovascular disease with PPAR modulators

L9 ANSWER 27 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN

TI Use of agonists of the peroxisome proliferator activated receptor  $\alpha$  for treating obesity

L9 ANSWER 28 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN

TI Generation of secondary alkyl amines on solid support by borane reduction. Application to the parallel synthesis of PPAR ligands

L9 ANSWER 29 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN

TI Potent hypocholesterolemic activity of novel ureido phenoxyisobutyrate correlates with their intrinsic fibrate potency and not with their ACAT inhibitory activity

L9 ANSWER 30 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN

TI Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors  $\alpha$  and  $\gamma$

L9 ANSWER 31 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN

TI Preparation of antiatherosclerotic diaryl ureas

=> d 19 21-31 ti fbib abs

L9 ANSWER 21 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN

TI Pharmaceutical compositions containing ACAT and MMP inhibitors for the treatment of atherosclerotic lesions

AN 2000:84604 CAPLUS

DN 132:141951

TI Pharmaceutical compositions containing ACAT and MMP inhibitors for the treatment of atherosclerotic lesions

IN Bocan, Thomas Michael Andrew

PA Warner-Lambert Company, USA

SO PCT Int. Appl., 222 pp.  
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000004892	A2	20000203	WO 1999-US13948	19990618
	WO 2000004892	A3	20000518		
	W:	AE, AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2335062	AA	20000203	US 1998-93639P P	19980721
				CA 1999-2335062	19990618



			US 1998-93639P P 19980721
			WO 1999-US13948W 19990618
AU 9947017	A1	20000214	AU 1999-47017 19990618
			US 1998-93639P P 19980721
			WO 1999-US13948W 19990618
BR 9912296	A	20010417	BR 1999-12296 19990618
			US 1998-93639P P 19980721
			WO 1999-US13948W 19990618
EP 1098662	A2	20010516	EP 1999-930483 19990618
			R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
			US 1998-93639P P 19980721
			WO 1999-US13948W 19990618
EE 200100046	A	20020617	EE 2001-46 19990618
			US 1998-93639P P 19980721
			WO 1999-US13948W 19990618
JP 2002521328	T2	20020716	JP 2000-560885 19990618
			US 1998-93639P P 19980721
			WO 1999-US13948W 19990618
ZA 2001000294	A	20020110	ZA 2001-294 20010110
			US 1998-93639P P 19980721
BG 105162	A	20011231	BG 2001-105162 20010117
			US 1998-93639P P 19980721
			WO 1999-US13948W 19990618
NO 2001000291	A	20010118	NO 2001-291 20010118
			US 1998-93639P P 19980721
			WO 1999-US13948W 19990618
HR 2001000055	A1	20020430	HR 2001-55 20010119
			US 1998-93639P P 19980721
			WO 1999-US13948W 19990618
AB	<p>Acyl-CoA:cholesterol acyltransferase (ACAT) and matrix metalloproteinase (MMP) inhibitors are coadministered for the reduction of both the macrophage and smooth muscle cell component of atherosclerotic lesions, thus impairing the expansion of existing lesions and the development of new lesions and for the prevention of plaque rupture and the promotion of lesion regression in a mammal. The direct antiatherosclerotic potential of the combination of ACAT inhibitor, [[2,4,6-tris-(1-methyl)phenyl]acetyl]-2,6-bis(1-methylethyl)phenyl sulfamic acid, and the HMG-CoA reductase inhibitor, simvastatin, in rabbits was studied. A tablet contained 2-(4'-bromobiphenyl-4-sulfonylamino)-3-Me butyric acid 25 ACAT compound lactose 50, corn starch 20, and magnesium stearate 5 mg.</p>		
L9	ANSWER 22 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN		
TI	A Ureido-Thioisobutyric Acid (GW9578) Is a Subtype-Selective PPAR $\alpha$ Agonist with Potent Lipid-Lowering Activity		
AN	1999:567006 CAPLUS		
DN	131:306978		
TI	A Ureido-Thioisobutyric Acid (GW9578) Is a Subtype-Selective PPAR $\alpha$ Agonist with Potent Lipid-Lowering Activity		
AU	Brown, Peter J.; Winegar, Deborah A.; Plunket, Kelli D.; Moore, Linda B.; Lewis, Michael C.; Wilson, Joan G.; Sundseth, Scott S.; Koble, Cecilia S.; Wu, Zhengdong; Chapman, James M.; Lehmann, Juergen M.; Klierer, Steven A.; Willson, Timothy M.		
CS	Departments of Medicinal Chemistry Metabolic Diseases and Molecular Endocrinology, Glaxo Wellcome Research & Development, Research Triangle Park, NC, 27709, USA		
SO	Journal of Medicinal Chemistry (1999), 42(19), 3785-3788 CODEN: JMCMAR; ISSN: 0022-2623		
PB	American Chemical Society		
DT	Journal		
LA	English		
AB	Several fibrates and ureido-fibrates were compared for their agonist activity at the PPAR $\alpha$ (peroxisome proliferator-activated		

receptor- $\alpha$ ). The ureido-fibrates were potent agonists at murine PPAR $\alpha$ ; however, like the fibrates, they showed only moderate levels of subtype selectivity. The ureido-thioisobutyric acid derivative (GW9578) was prepared and shown to be a selective PPAR $\alpha$  agonist. The lipid-lowering activity of the fibrates and GW9578 were determined: GW9578 had good activity. The lipid-lowering activity of the fibrates was correlated with their lipid-lowering activity. GW9578 decreased total LDL cholesterol and apoC-III levels, indicating that its mechanism was clin. relevant.

RE.CNT 25      THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9      ANSWER 23 OF 31    CAPLUS    COPYRIGHT 2004 ACS on STN  
TI      Direct tritium labeling of multifunctional compounds using organoiridium catalysis. 2  
AN      1999:525826    CAPLUS  
DN      131:299124  
TI      Direct tritium labeling of multifunctional compounds using organoiridium catalysis. 2  
AU      Shu, A. Y. L.; Saunders, D.; Levinson, S. H.; Landvatter, S. W.; Mahoney, A.; Senderoff, S. G.; Mack, J. F.; Heys, J. R.  
CS      Radiochemistry, SmithKline Beecham Pharmaceuticals, King of Prussia, PA, 19406, USA  
SO      Journal of Labelled Compounds & Radiopharmaceuticals (1999), 42(8), 797-807  
CODEN: JLCRD4; ISSN: 0362-4803  
PB      John Wiley & Sons Ltd.  
DT      Journal  
LA      English  
AB      A variety of complex compds. were labeled with tritium gas by catalytic exchange in the presence of catalyst precursors [(cod)Ir(dppe)]BF<sub>4</sub> or [(cod)Ir(py)(PCy<sub>3</sub>)]BF<sub>4</sub>. In most cases, predictable regioselectivity and high specific activities are achieved. These results are compared in some cases to the results of labeling related compds. with [(cod)Ir(PPh<sub>3</sub>)<sub>2</sub>]BF<sub>4</sub>. Preredn. of the catalyst precursors in situ with hydrogen allows the use of smaller quantities of tritium gas and reduces the amount of radioactive waste. Two or more compds. can be labeled simultaneously as mixts. then separated in the HPLC purification step to increase compound throughput.

RE.CNT 9      THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9      ANSWER 24 OF 31    CAPLUS    COPYRIGHT 2004 ACS on STN  
TI      Identification of peroxisome proliferator-activated receptor ligands from a biased chemical library  
AN      1999:474434    CAPLUS  
Correction of: 1998:80482  
DN      131:97348  
Correction of: 128:215212  
TI      Identification of peroxisome proliferator-activated receptor ligands from a biased chemical library  
AU      Brown, Peter J.; Smith-Oliver, Tracey A.; Charifson, Paul S.; Tomkinson, Nicholas C. O.; Fivush, Adam M.; Sternbach, Daniel D.; Wade, Laura E.; Orband-Miller, Lisa; Parks, Derek J.; Blanchard, Steven G.  
CS      Dep. Medicinal Chem., Wellcome Research & Development, Research Triangle, NC, 27709-3398, USA  
SO      Chemistry & Biology (1997), 4(12), 909-918  
CODEN: CBOLE2; ISSN: 1074-5521  
PB      Current Biology Ltd.  
DT      Journal  
LA      English  
AB      Background: The peroxisome proliferator-activated receptors (PPARs) were cloned as orphan members of the nuclear receptor superfamily of transcription factors. The identification of subtype-selective ligands

for PPAR $\alpha$  and PPAR $\gamma$  has led to the discovery of their roles in the regulation of lipid metabolism and glucose homeostasis. No subtype-selective PPAR $\delta$  ligands are available and the function of this subtype is currently unknown. Results: A three-component library was designed in which one of the monomers was biased towards the PPARs and the other two monomers were chosen to add chemical diversity. Synthesis and screening of the library resulted in the identification of pools with activity on each of the PPAR subtypes. Deconvolution of the pools with the highest activity on PPAR $\delta$  led to the identification of GW 2433 as the first high-affinity PPAR $\delta$  ligand. [3H]GW 2433 is an effective radioligand for use in PPAR $\delta$  competition-binding assays. Conclusions: The synthesis of biased chemical libraries is an efficient approach to the identification of lead mols. for members of sequence-related receptor families. This approach is well suited to the discovery of small-mol. ligands for orphan receptors.

L9 ANSWER 25 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN  
 TI Generation of secondary alkyl amines on solid support by borane reduction. Applications to the parallel synthesis of PPAR ligands. [Erratum to document cited in CA127:220440]  
 AN 1999:157196 CAPLUS  
 DN 130:267199  
 TI Generation of secondary alkyl amines on solid support by borane reduction. Applications to the parallel synthesis of PPAR ligands. [Erratum to document cited in CA127:220440]  
 AU Brown, Peter J.; Hurley, Kevin P.; Stuart, L. William; Wilson, Timothy M.  
 CS Department Medicinal Chemistry, Glaxo Wellcome Research Development, Research Triangle Park, NC, 27709, USA  
 SO Synthesis (1999), (2), 364  
 CODEN: SYNTBF; ISSN: 0039-7881  
 PB Georg Thieme Verlag  
 DT Journal  
 LA English  
 AB On page 780, column 2, line 7, the abbreviation DIC should read as diisopropylcarbodiimide.

L9 ANSWER 26 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN  
 TI Prevention or treatment of type 2 diabetes or cardiovascular disease with PPAR modulators  
 AN 1998:112233 CAPLUS  
 DN 128:176165  
 TI Prevention or treatment of type 2 diabetes or cardiovascular disease with PPAR modulators  
 IN Paterniti, James R.; Briggs, Michael R.; Mukherjee, Ranjan; Auwerx, Johan; Stael, Bart  
 PA Ligand Pharmaceuticals Inc., USA  
 SO PCT Int. Appl., 62 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9805331	A2	19980212	WO 1997-US13605	19970801
	WO 9805331	A3	19980507		
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				

AU 9740507                    A1    19980225                    US 1996-22949P P 19960802  
    AU 1997-40507    19970801  
    US 1996-22949P P 19960802  
    WO 1997-US13605W 19970801  
 EP 930882                    A2    19990728                    EP 1997-938101    19970801  
    R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI  
    US 1996-22949P P 19960802  
    WO 1997-US13605W 19970801

AB    This invention relates to methods and compns. for the prevention and treatment of Type 2 diabetes and cardiovascular disease with diabetic or pre-diabetic conditions or symptoms associated therewith using both a PPAR $\gamma$  (Peroxisome proliferator activated receptor) agonist and a PPAR $\alpha$  agonist or a compound which activates both PPAR $\gamma$  and PPAR $\alpha$ . A preferred PPAR $\gamma$  agonist is a thiazolidinedione compound, including BRL 49653, troglitazone, pioglitazone, ciglitazone, WAY-120,744, englitazone, AD 5075, darglitazone, and congeners, analogs, derivs. and pharmaceutically acceptable salts thereof. A preferred PPAR $\alpha$  agonist is a fibrate compound including gemfibrozil, fenfibrate, bezofibrate, clofibrate, ciprofibrate, and analogs, derivs. and pharmaceutically acceptable salts thereof. An example is given showing that a PPAR $\gamma$  agonist and a PPAR $\alpha$  agonist in combination achieved enhanced antidiabetic and cardioprotective effects over either agent alone.

L9    ANSWER 27 OF 31    CAPLUS    COPYRIGHT 2004 ACS on STN  
 TI    Use of agonists of the peroxisome proliferator activated receptor  $\alpha$  for treating obesity  
 AN    1997:672266    CAPLUS  
 DN    127:326560  
 TI    Use of agonists of the peroxisome proliferator activated receptor  $\alpha$  for treating obesity  
 IN    Willson, Timothy Mark  
 PA    Glaxo Group Ltd., UK; Willson, Timothy Mark  
 SO    PCT Int. Appl., 21 pp.  
       CODEN: PIXXD2  
 DT    Patent  
 LA    English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9736579	A1	19971009	WO 1997-EP1552	19970327
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			

AU 9725061	A1	19971022	GB 1996-6805	A 19960330
			AU 1997-25061	19970327
			GB 1996-6805	A 19960330
			WO 1997-EP1552	W 19970327
ZA 9702685	A	19971120	ZA 1997-2685	19970327
			GB 1996-6805	A 19960330
US 6028109	A	20000222	US 1998-155321	19980928
			GB 1996-6805	A 19960330
			WO 1997-EP1552	W 19970327

AB    The invention discloses the use of agonists of the peroxisome proliferator activated receptor  $\alpha$  (PPAR $\alpha$ ) for the manufacture of a medicament for the treatment of obesity, as well as methods of treating obesity comprising the administration of a therapeutic amount of a PPAR $\alpha$  agonist. Preparation of 2-[4-(2-(3-(4-fluorophenyl)-1-

heptylureido)ethyl)phenoxy]-2-methylpropionic acid is described, as are preparation of the corresponding tritiated radioligand, binding data, and weight loss data.


- L9 ANSWER 28 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN  
TI Generation of secondary alkyl amines on solid support by borane reduction. Application to the parallel synthesis of PPAR ligands  
AN 1997:505482 CAPLUS  
DN 127:220440  
TI Generation of secondary alkyl amines on solid support by borane reduction. Application to the parallel synthesis of PPAR ligands  
AU Brown, Peter J.; Hurley, Kevin P.; Stuart, L. William; Willson, Timothy M.  
CS Department Medicinal Chemistry, Glaxo Wellcome Research Development, Research Triangle Park, NC, 27709, USA  
SO Synthesis (1997), (7), 778-782  
CODEN: SYNTBF; ISSN: 0039-7881  
PB Thieme  
DT Journal  
LA English  
OS CASREACT 127:220440  
AB A solid-phase parallel synthesis of fibrate peroxisome proliferator-activated receptor (PPAR) ligands, 4-(HO<sub>2</sub>CCMe<sub>2</sub>O)C<sub>6</sub>H<sub>4</sub>(CH<sub>2</sub>)<sub>2</sub>NRCONHR<sub>1</sub> [R = heptyl, Ph(CH<sub>2</sub>)<sub>2</sub>, PhOCHMeCH<sub>2</sub>, 3,5-(CF<sub>3</sub>)<sub>2</sub>C<sub>6</sub>H<sub>3</sub>CH<sub>2</sub>; R<sub>1</sub> = 4-FC<sub>6</sub>H<sub>4</sub>, 2,4-(MeO)<sub>2</sub>C<sub>6</sub>H<sub>3</sub>, 4-AcC<sub>6</sub>H<sub>4</sub>, 2,3-Cl<sub>2</sub>C<sub>6</sub>H<sub>3</sub>] was developed. The key reaction is a novel borane reduction of resin bound amides that generates secondary amines not accessible by reductive alkylation of primary amines. 4-(HO<sub>2</sub>CCMe<sub>2</sub>O)C<sub>6</sub>H<sub>4</sub>(CH<sub>2</sub>)<sub>2</sub>NHfmoc (fmoc = 9-fluorenylmethoxycarbonyl) was loaded onto Sasrin resin via the carboxylic acid. The amine was elaborated by amide bond formation followed by reduction with borane. The resulting secondary amines reacted with aryl isocyanates to generate the fibrates in high yield and purity following cleavage from the solid support.
- L9 ANSWER 29 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN  
TI Potent hypocholesterolemic activity of novel ureido phenoxyisobutyrate correlates with their intrinsic fibrate potency and not with their ACAT inhibitory activity  
AN 1997:428048 CAPLUS  
DN 127:144748  
TI Potent hypocholesterolemic activity of novel ureido phenoxyisobutyrate correlates with their intrinsic fibrate potency and not with their ACAT inhibitory activity  
AU Hawke, Roy L.; Chapman, James M.; Winegar, Deborah A.; Salisbury, Jo A.; Welch, Richard M.; Brown, Alan; Franzmann, Karl W.; Sigel, Carl  
CS Division of Pharmacokinetics and Drug Metabolism, Wellcome Research Laboratories, Research Triangle Park, NC, 27709, USA  
SO Journal of Lipid Research (1997), 38(6), 1189-1203  
CODEN: JLPRAW; ISSN: 0022-2275  
PB Lipid Research, Inc.  
DT Journal  
LA English  
AB The hypocholesterolemic activity for novel ureido fibrate analogs was over 100-fold greater than for any "second-generation" fibrate in cholesterol-fed rats. A comparison of 12 related analogs revealed that the optimal configuration for a urea-bridging region located between two aromatic rings consisted of a trisubstituted nitrogen, optimally substituted with a C<sub>7</sub> alkyl chain and linked by dimethylene to a phenoxyisobutyrate moiety found in most fibrate analogs. The hypocholesterolemic potency of these compds. was found to correlate with their increased intrinsic fibrate activity as determined by the ability to induce ω-hydroxylase activity either in rat hepatocyte cultures or in vivo, and not with their 10-fold increased ACAT inhibitory potency when compared to other fibrates.

The most active compound, 2-(4-(2-(N'-(2,4-difluorophenyl)-N-heptylureido)ethyl)phenoxy)-2-methylpropionic acid (I) was found to induce  $\omega$ -hydroxylase activity in hepatocytes in concns. between 5 and 100 nM compared to 1-20  $\mu$ M concns. for bezafibrate, and lower serum VLDL + LDL cholesterol in rats at doses between 0.1 and 0.5 mg/kg per day compared to doses of 25-100 mg/kg per day for bezafibrate. Single-dose pharmacokinetic studies with I indicated that total drug exposure will be much lower at hypocholesterolemic doses due to the enhanced intrinsic activity, and may result in an improved safety profile for these novel trisubstituted ureido fibrate analogs in rats and humans compared to other fibrates.

- L9 ANSWER 30 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN  
 TI Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors  $\alpha$  and  $\gamma$   
 AN 1997:308252 CAPLUS  
 DN 127:30658  
 TI Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors  $\alpha$  and  $\gamma$   
 AU Kliewer, Steven A.; Sundseth, Scott S.; Jones, Stacey A.; Brown, Peter J.; Wisely, G. Bruce; Koble, Cecilia; Devchand, Pallavi; Wahli, Walter; Willson, Timothy M.; Lenhard, James M.; Lehmann, Jurgen M.  
 CS Departments of Molecular Endocrinology, Metabolic Diseases, Medicinal Chemistry and Structural Chemistry, Glaxo Wellcome Research and Development, Research Triangle Park, NC, 27709, USA  
 SO Proceedings of the National Academy of Sciences of the United States of America (1997), 94(9), 4318-4323  
 CODEN: PNASA6; ISSN: 0027-8424  
 PB National Academy of Sciences  
 DT Journal  
 LA English  
 AB Peroxisome proliferator-activated receptors (PPARs)  $\alpha$  and  $\gamma$  are key regulators of lipid homeostasis and are activated by a structurally diverse group of compds. including fatty acids, eicosanoids, and hypolipidemic drugs such as fibrates and thiazolidinediones. While thiazolidinediones and 15-deoxy- $\Delta$ 12,14-prostaglandin J2 have been shown to bind to PPAR $\gamma$ , it has remained unclear whether other activators mediate their effects through direct interactions with the PPARs or via indirect mechanisms. Here, a novel fibrate designed GW2231 is described, that is a high-affinity ligand for both PPAR $\alpha$  and PPAR $\gamma$ . Using GW2331 as a radioligand in competition binding assays, it is shown that certain mono- and polyunsatd. fatty acids bind directly to PPAR $\alpha$  and PPAR $\gamma$  at physiol. concns., and that the eicosanoids 8(S)-hydroxyeicosatetraenoic acid and 15-deoxy- $\Delta$ 12,14-prostaglandin J2 can function as subtype-selective ligands for PPAR $\alpha$  and PPAR $\gamma$ , resp. These data provide evidence that PPARs serve as physiol. sensors of lipid levels and suggest a mol. mechanism whereby dietary fatty acids can modulate lipid homeostasis.
- L9 ANSWER 31 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN  
 TI Preparation of antiatherosclerotic diaryl ureas  
 AN 1992:612163 CAPLUS  
 DN 117:212163  
 TI Preparation of antiatherosclerotic diaryl ureas  
 IN Franzmann, Karl Witold; O'Connor, Kevin Julian; Hawke, Roy Lee; Chapman, James Mood  
 PA Wellcome Foundation Ltd., UK; University of South Carolina  
 SO PCT Int. Appl., 42 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9210468	A1	19920625	WO 1991-GB2195	19911211
	W: AU, CA, HU, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
	CA 2098122	AA	19920613	GB 1990-27023 A	19901212
				CA 1991-2098122	19911211
				GB 1990-27023 A	19901212
	AU 9190560	A1	19920708	AU 1991-90560	19911211
	AU 647859	B2	19940331		
				GB 1990-27023 A	19901212
				WO 1991-GB2195 A	19911211
	ZA 9109773	A	19930611	ZA 1991-9773	19911211
				GB 1990-27023 A	19901212
	HU 64514	A2	19940128	HU 1993-1709	19911211
				GB 1990-27023 A	19901212
	JP 06507151	T2	19940811	JP 1991-501716	19911211
	JP 2951402	B2	19990920		
				GB 1990-27023 A	19901212
				WO 1991-GB2195 W	19911211
	EP 639178	A1	19950222	EP 1992-900716	19911211
	EP 639178	B1	19970903		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
				GB 1990-27023 A	19901212
				WO 1991-GB2195 W	19911211
	IL 100331	A1	19960912	IL 1991-100331	19911211
				GB 1990-27023 A	19901212
	AT 157651	E	19970915	AT 1992-900716	19911211
				GB 1990-27023 A	19901212
	US 5658944	A	19970819	US 1995-421997	19950414
				GB 1990-27023 A	19901212
				US 1991-805236 B1	19911211
				US 1992-962068 B3	19921016
OS	MARPAT 117:212163				
GI					



AB Title compds. I (Ar = (substituted) mono- or bicyclic aromatic group containing 1 or 2 heteroatoms; D = H2C, HN, O; E = N, CH, G = H, (substituted) C1-12 alkyl, -C1-12 aralkyl; I = bond, C1-6 alkylene; n = 0-10; R, R1 = H, (substituted) C1-8 alkyl, -C1-8 alkanoyl, NC, carboxyalkoxy, etc.; K = HOCH2, HCO, H2NCOCH2NHCO, R2O2C, wherein R2 = H, C1-8 alkyl, aryl heteroaryl, aralkyl, heteroalkyl, etc.) and salts thereof, are prepared Carbobenzyloxytyramine (preparation given) was converted in 5 steps to I [Ar = 2,4-(MeO)2C6H3, D = NH, E = N, G = 1-heptyl, I = CH2, n = 0, R = R1 = Me, K = HO2C] (II). II inhibited CoA: cholesterol acyl transferase with IC50 = 4.5 µM. Pharmaceutical formulations comprising I are given.

=> d his

(FILE 'HOME' ENTERED AT 11:41:50 ON 19 APR 2004)

FILE 'REGISTRY' ENTERED AT 11:42:02 ON 19 APR 2004

L1 STRUCTURE UPLOADED

L2 3 SEARCH L1 SSS SAM  
L3 75 SEARCH L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 11:45:58 ON 19 APR 2004  
L4 1 L3  
L5 0 LGOFF HOLD

FILE 'REGISTRY' ENTERED AT 11:53:08 ON 19 APR 2004  
L6 STRUCTURE UPLOADED  
L7 7 SEARCH L6 SSS SAM  
L8 111 SEARCH L6 SSS FULL

FILE 'CAPLUS' ENTERED AT 11:54:56 ON 19 APR 2004  
L9 31 L8

=> save temp l9 diabetcmpds/a  
ANSWER SET L9 HAS BEEN SAVED AS 'DIABETCMPDS/A'

=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	52.44	373.90
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-7.62	-8.31

SESSION WILL BE HELD FOR 60 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 12:23:51 ON 19 APR 2004

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'CAPLUS' AT 13:17:19 ON 19 APR 2004  
FILE 'CAPLUS' ENTERED AT 13:17:19 ON 19 APR 2004  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	52.44	373.90
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-7.62	-8.31

=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	52.88	374.34
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-7.62	-8.31

SESSION WILL BE HELD FOR 60 MINUTES



STN INTERNATIONAL SESSION SUSPENDED AT 13:17:50 ON 19 APR 2004

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'CAPLUS' AT 13:47:53 ON 19 APR 2004  
FILE 'CAPLUS' ENTERED AT 13:47:53 ON 19 APR 2004  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	52.88	374.34
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-7.62	-8.31

=> d his

(FILE 'HOME' ENTERED AT 11:41:50 ON 19 APR 2004)

FILE 'REGISTRY' ENTERED AT 11:42:02 ON 19 APR 2004

L1 STRUCTURE UPLOADED  
L2 3 SEARCH L1 SSS SAM  
L3 75 SEARCH L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 11:45:58 ON 19 APR 2004

L4 1 L3  
L5 0 LGOFF HOLD

FILE 'REGISTRY' ENTERED AT 11:53:08 ON 19 APR 2004

L6 STRUCTURE UPLOADED  
L7 7 SEARCH L6 SSS SAM  
L8 111 SEARCH L6 SSS FULL

FILE 'CAPLUS' ENTERED AT 11:54:56 ON 19 APR 2004

L9 31 L8  
SAVE TEMP L9 DIABETCMPDS/A

=> d l9 10-20 ti

L9 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN  
TI Modulation of bone formation with peroxisome proliferator-activated  
receptor activators and ligands

L9 ANSWER 11 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN  
TI Peroxisome proliferator-activated receptor subtype-specific regulation of  
hepatic and peripheral gene expression in the Zucker diabetic fatty rat

L9 ANSWER 12 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN  
TI Method for preparing a model system for cellular insulin resistance and  
device for use with the model system

L9 ANSWER 13 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN  
TI Preparation of substituted oxazoles and thiazoles as hPPAR alpha

activators

L9 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN  
TI Prevention of plaque rupture by ACAT inhibitors

L9 ANSWER 15 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN  
TI Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor

L9 ANSWER 16 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN  
TI PPAR $\alpha$  agonists inhibit tissue factor expression in human monocytes and macrophages

L9 ANSWER 17 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN  
TI Discrete roles for peroxisome proliferator-activated receptor  $\gamma$  and retinoid X receptor in recruiting nuclear receptor coactivators

L9 ANSWER 18 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN  
TI Alteration of a single amino acid in peroxisome proliferator-activated receptor- $\alpha$  (PPAR $\alpha$ ) generates a PPAR $\delta$  phenotype

L9 ANSWER 19 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN  
TI Chemical compounds as selective activators of PPAR alpha

L9 ANSWER 20 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN  
TI Preparation of substituted oxazoles and thiazoles as hPPAR gamma and hPPAR alpha activators

=> d 19 19 ti fbib abs

L9 ANSWER 19 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN  
TI Chemical compounds as selective activators of PPAR alpha  
AN 2000:277947 CAPLUS  
DN 132:308064  
TI Chemical compounds as selective activators of PPAR alpha  
IN Brown, Peter Jonathan; Chapman, James Mood; Oplinger, Jeffrey Alan; Stuart, Ludwig William; Willson, Timothy Mark; Wu, Zhengdong  
PA Glaxo Group Ltd., UK; University of South Carolina  
SO PCT Int. Appl., 32 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000023407	A2	20000427	WO 1999-GB3420	19991015
	WO 2000023407	A3	20000803		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				GB 1998-22473	A 19981016
AU 9963506	A1	20000508		AU 1999-63506	19991015
				GB 1998-22473	A 19981016
				WO 1999-GB3420	W 19991015
EP 1149063	A2	20011031		EP 1999-950913	19991015
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO

JP 2002527496 T2 20020827

US 6306854 B1 20011023

OS MARPAT 132:308064

GI

GB 1998-22473 A 19981016  
WO 1999-GB3420 W 19991015  
JP 2000-577136 19991015  
GB 1998-22473 A 19981016  
WO 1999-GB3420 W 19991015  
US 2001-806890 20010416  
GB 1998-22473 A 19981016  
WO 1999-GB3420 W 19991015

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. [I; m = 0-20; R6 = (un)substituted-cyclohexyl, (un)substituted-Ph;; R8 = (un)substituted-cyclohexyl, (un)substituted-cyclohexylmethyl, (un)substituted-cyclohexylethyl, (un)substituted-Ph, (un)substituted-phenylmethyl, (un)substituted-phenylethyl], ester, salt, physiol. functional derivs., and pharmaceutical composition comprising title compound are prepared and tested as activators of PPAR alpha and used in therapy treating obesity, dyslipidemia, Alzheimer's disease, atherosclerosis, or diabetes. The title compound II was prepared

=> logoff hold

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
61.07	382.53

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-8.32	-9.01

CA SUBSCRIBER PRICE

SESSION WILL BE HELD FOR 60 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 13:50:42 ON 19 APR 2004